SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the following letter to its stockholders from its President & Chief Executive Officer, Steven Lo.

Friday’s game was also the finale for Coachman, who confirmed after the game his plan to retire from coaching. He guided the ...

Pfizer has had a rough year, underperforming both the broader market and its pharmaceutical peers. Shares are down 4.7% over ...

A BAR and restaurant chain beloved by celebrities has closed three of its sites for good. Horticulture shut its city-centre location in Newcastle as well as its coastal venue in nearby Whitley Bay ...

Louisiana Surgeon General Ralph Abraham backs bill to deregulate the drug ivermectin and recommends it to his own patients.

Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), ...

Pfizer (PFE) stock slips after the company's lower than expected Q1 2025 revenue and the firm seeks acquisitions to boost its ...

Earlier this month, study results showed that molnupiravir, Merck’s investigational antiviral pill, cut hospitalization rates ...

In February, the HHS unexpectedly delivered notice that the South San Francisco-based company was to stop all work on the ...

The three companies issued stop work orders are developing COVID-19 vaccines that use new technology to improve effectiveness ...

Stephanie Armour was formerly a senior special writer for health policy at The Wall Street Journal, where she covered such topics as the Covid-19 pandemic, the Affordable Care Act, Medicaid and ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...